Translations:Resveratrol/39/en: Difference between revisions
(Importing a new version from external source) |
(Importing a new version from external source) |
||
Line 1: | Line 1: | ||
{| class="wikitable mw-collapsible mw-collapsed" style="width: 100%;" | {| class="wikitable mw-collapsible mw-collapsed" style="width: 100%;" | ||
|+Reported resveratrol plasma concentration in humans after repeated doses of resveratrol (studies after 2010). {{ | |+Reported resveratrol plasma concentration in humans after repeated doses of resveratrol (studies after 2010). {{pmid|30641865}} | ||
!Number of Participants, Characteristics, Study Type | !Number of Participants, Characteristics, Study Type | ||
!Dose<br>(mg/day) | !Dose<br>(mg/day) |
Latest revision as of 03:54, 11 February 2024
Number of Participants, Characteristics, Study Type | Dose (mg/day) |
Days | Administration | Peak Plasma Concentration (ng/mL) |
---|---|---|---|---|
6, low BMI | 2125 | 11 | Tablet and drink | 903.0 |
6, high BMI | 245.0 | |||
35, healthy males, cross-over study | 800 | 5 | Capsule | 0.56 |
Dairy drink | 0.61 | |||
Soy drink | 0.58 | |||
Protein-free drink | 0.70 | |||
7, healthy | 500 | 28 | Capsule with Piperine | 2967.25 |
40, healthy, repeated sequential dosing | 500 | 29 | Caplet | 43.8 |
1000 | 141 | |||
2500 | 331 | |||
5000 | 967 | |||
6, patients with hepatic metastases, randomized double-blind clinical trial | 5000 | 14 | Micronized resveratrol mixed in liquid | 1942 |
8, healthy subjects | 2000 | 7 | Capsule | 1274 |
19, overweight or obese, randomized, double-blind, placebo-controlled, crossover intervention | 30 | 6 | Capsule | 181.31 |
90 | 532.00 | |||
270 | 1232.16 |
- ↑ Springer M & Moco S: Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity. Nutrients 2019. (PMID 30641865) [PubMed] [DOI] [Full text] Resveratrol is one of the most widely studied polyphenols and it has been assigned a plethora of metabolic effects with potential health benefits. Given its low bioavailability and extensive metabolism, clinical studies using resveratrol have not always replicated in vitro observations. In this review, we discuss human metabolism and biotransformation of resveratrol, and reported molecular mechanisms of action, within the context of metabolic health and obesity. Resveratrol has been described as mimicking caloric restriction, leading to improved exercise performance and insulin sensitivity (increasing energy expenditure), as well as having a body fat-lowering effect by inhibiting adipogenesis, and increasing lipid mobilization in adipose tissue. These multi-organ effects place resveratrol as an anti-obesity bioactive of potential therapeutic use.